Interestingly, the FCSRT‐96 stood out for its consistent associations with MTL structure, aligning with prior studies linking it to early tau burden in preclinical AD and highlighting its value among PACC‐5 subtests for distinguishing preclinical AD from healthy aging over time.46, 77. This evidence concerns the gene MAPT and Alzheimer disease.